The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...

May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's (VSTM.O), opens new tab combination therapy for patients with a rare type of ovarian cancer who have received prior ...

Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...

US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the FDA’s new artificial intelligence effort in ...

The US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) ...

The Food and Drug Administration on Thursday granted accelerated approval to Verastem Inc.’s (NASDAQ:VSTM) Avmapki Fakzynja Co-pack, a combination of avutometinib and defactinib for adult patients ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...